Mindray Medical: (NYSE: MR)

$41.27

-0.21 (-0.51%)

Volume 494,252

May 22 04:06 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		41.19 - 41.97
	
		52wk Low - High
		28.26 - 42.40
	
		Previous Close
		41.48
	
		Avg. Volume
		848,232
	
		Industry
		MED INSTRUMENTS
	
		Market Cap
		4.85 B
	
		Div - Yield
		0.46 - 1.11
	
		Beta
		1.22
	
		PE (Forward)
		20.47
	
		Current Year Est.
		2.02
	
		Quarterly Earnings ESP 
		-3.77%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		121 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 03/8/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            20.47
                        
                            PEG Ratio
                            1.44
                        
                            Current Year Est.
                            2.02
                        
                            Current Quarter Estimate
                            0.53
                        
                            Most Accurate Estimate
                            0.51
                        
                            Earnings ESP 
                            -3.77%
                        
                            Next Earnings Report Date
                            08-05-2013
                        
                            EPS Last Year
                            1.83
                        
                            Expected Earnings Growth
                            14.23%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices in China with a significant and growing presence worldwide. Mindray offers a broad range of products across three primary business segments: patient monitoring devices, diagnostic laboratory instruments, and ultrasound imaging systems. Mindray is headquartered in Shenzhen, China, and has twenty nine local sales and services offices in China, as well as sales and services offices in Boston, Istanbul, London and Vancouver.   
Full MR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.53	0.46	2.02	2.25
Number of Estimates	3	3	5	6
Low Estimate	0.48	0.42	1.90	2.09
High Estimate	0.58	0.50	2.16	NA
Year Ago EPS	0.45	0.39	1.65	2.02
EPS Growth	18.52%	18.80%	22.18%	11.36%

More MR Estimates

Average Earnings Estimates for MR

EPS Growth for MR

Industry Analysis

Name	Symbol	Previous Close
MINDRAY MEDICAL	MR	41.27
NATUS MEDICAL	BABY	14.05
CRYOLIFE INC	CRY	6.31
DELCATH SYS INC	DCTH	0.42
GLOBUS MEDICAL	GMED	15.29
HEARTWARE INTL	HTWR	92.81
MELA SCIENCES	MELA	1.08
OXYSURE SYSTEMS	OXYS	0.81
PACIFIC BIOSCI	PACB	2.45
SUNSHINE HEART	SSH	5.88

Sector:Medical>> Industry:MED INSTRUMENTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Mindray Beats Earnings Est, Misses Rev

May 07, 2013

Volcano Beats Earnings, Downturn Ahead

May 07, 2013

HOLX Beats Earnings, View Slashed

May 07, 2013

Abiomed Earnings Beat in 4Q

May 03, 2013

Dismal Earnings Miss by Omnicell

May 03, 2013

More Backing for HOLX Tomosynthesis

Apr 17, 2013

Mindray to Exhibit at CMEF

Apr 04, 2013

Abiomed Remains Neutral

Mar 22, 2013

More MR Zacks Commentary

Financials

EPS TTM	1.83
Sales	1,060
Net Income	201
Price/Earnings	22.55
Price/Book	3.50
Price/Cash Flow	24.51
Price/Sales	4.47

More MR Financials

News

Rash Of Breakouts A Bullish Sign For Foreign Stocks - Investors Business Daily

May 22, 2013

Mindray Announces its Recent Filing of Annual Report on Form 20-F with the U.S. Securities and Exchange Commission - Pr Newswire

May 21, 2013

Possible Bearish Inside Day Candle Pattern Detected for Mindray Medical International (NYSE:MR) - Financial News Network Online - News Corner

May 21, 2013

Potential Mindray Medical International (MR) Trade Has $39.96 Breakeven - Freshbrewedmedia

May 21, 2013

Recent 52-Week High Exceeded in Shares of Mindray Medical International (MR) - Financial News Netwfork Online - 52-Week High-Lows

May 21, 2013

Something`s Up At China-Based Mindray Medical - Investors Business Daily

May 20, 2013

Mindray Medical International: The Winning Streak Continues (MR) - Financial News Netwfork Online - 52-Week High-Lows

May 17, 2013

Mindray Medical Q1 net income increases - Datamonitor

May 17, 2013

See All News Stories on MR

Broker Recommendations

Current ABR	2.14
ABR (Last Week)	2.14
# of recs in ABR	7
Average Target Price	39.33
Industry Rank by ABR	121 out of 265
Rank in Industry	10 out of 54

More MR Broker Recommendations

Day Low - High	41.19 - 41.97
52wk Low - High	28.26 - 42.40
Previous Close	41.48
Avg. Volume	848,232
Industry	MED INSTRUMENTS
Market Cap	4.85 B
Div - Yield	0.46 - 1.11
Beta	1.22
PE (Forward)	20.47
Current Year Est.	2.02
Quarterly Earnings ESP	-3.77%

PE (Forward)	20.47
PEG Ratio	1.44
Current Year Est.	2.02
Current Quarter Estimate	0.53
Most Accurate Estimate	0.51
Earnings ESP	-3.77%
Next Earnings Report Date	08-05-2013
EPS Last Year	1.83
Expected Earnings Growth	14.23%

Username: Password:

Remember me [?]

Mindray Medical: (NYSE: MR)

$41.27

-0.21 (-0.51%)

Volume 494,252

May 22 04:06 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED INSTRUMENTS

Zacks Commentary

Financials

News

Broker Recommendations